盐酸吡格列酮对大鼠高脂饮食性脂肪肝的预防和治疗作用  

Preventive and therapeutic effects of pioglitazone on fatty liver induced by high-fat feeding in rats

作　　者：张会娟[1] 李建生[2] 李道明[3] 张志宇[1] 段艳峰[1] 赵志华[3] 

机构地区：[1]郑州大学第一附属医院内分泌科,河南省郑州市450052 [2]郑州大学第一附属医院消化内科(河南省高等学校临床医学重点学科开放实验室),河南省郑州市450052 [3]郑州大学第一附属医院病理科(河南省肿瘤病理重点实验室),河南省郑州市450052

出　　处：《中国临床康复》2006年第32期60-62,i0001,共4页Chinese Journal of Clinical Rehabilitation

摘　　要：目的:观察吡格列酮对大鼠高脂饮食性脂肪肝的预防和治疗作用,并对其预防和治疗的效果进行比较。方法:实验于2005-01/07在河南省实验动物中心和河南省肿瘤病理重点实验室进行。取36只SD大鼠单纯随机分为2个系列6组:①预防系列分为10周处死正常组(n=6)、10周处死模型组(n=6)和吡格列酮预防组(n=7)3个组,10周处死正常组给予标准饲料,其他2组给予高脂饮食(标准饲料的基础上加13%的猪油、2%的胆固醇),饲养3周时吡格列酮预防组给予盐酸吡格列酮(杭州中美华东制药有限公司生产)20mg/(kg·d)灌胃,其他2组等量蒸馏水灌胃,饲养10周均处死。②治疗系列分为17周处死正常组(n=5)、17周处死模型组(n=5)和吡格列酮治疗组(n=7)3个组,17周处死正常组给予标准饲料,其他2组给予高脂饮食,饲养10周时吡格列酮治疗组给予盐酸吡格列酮20mg/(kg·d)灌胃,其他2组等量蒸馏水灌胃,饲养17周均处死。观测各组动物终末体质量、血清转氨酶、血脂、血糖、胰岛素、肝内脂质含量及病理组织学改变。结果:32只大鼠进入结果分析。①预防系列组结果:吡格列酮预防组肝指数(肝质量/体质量)、血清和肝脏三酰甘油、HOMA胰岛素抵抗指数和肝脂变程度均显著低于10周处死模型组(P<0.01或P<0.05),与10周处死正常组比较差异不显著(P>0.05)。三组之间血清及肝内胆固醇浓度比较差异不显著(P>0.05)。②治疗系列组结果:吡格列酮治疗组肝指数、血清转氨酶、胰岛素、三酰甘油、肝脏三酰甘油、HOMA胰岛素抵抗指数和肝脂变程度均明显低于17周处死模型组(P<0.01或0.05),但与17周处死正常组比较仍有显著差异(P<0.01或P<0.05)。吡格列酮治疗组和17周处死模型组血清及肝内总胆固醇浓度高于17周处死正常组(P<0.01),但前2组间比较差异不显著(P>0.05)。结论:吡格列酮通过降脂和改善胰岛素敏感性,具有预防和治疗大鼠高脂AIM： To explore the preventive and therape.utic effects of pioglitazone on rats with fatty liver induced by high fat feeding, and compare the preventive effect with curative effect. METHODS： The experiment was carried out in Henan Provincial Experimental Animal Center and Henan Key Laboratory on Tumor Pathology from January to July 2005. Thirty-six Spragne-Dawley rats were randomly divided into 2 series of 6 groups： ①The preventive series was divided into 10-week execution nomaal group （n=6） and 10-week execution model group （n=6） as well as pioglitazone preventive group （n=7）. Rats in 10-week nomaal group were fed with standard diet and rats in the other two groups were fed with high-fat diet （based on standard diet, 13% of pig fats and 2% of cholesterol were added）. Rats in 10-week pioglitazone preventive group received gastric perfusion of 20 mg/kg pioglitazone （manufactured by Hangzhou China-American Huadong Pharmaceutical Co., Ltd） per day at the 3^rd week of feeding, while rats in the other two groups received gastric perfusion of distilled water at the same volume and were executed at the 10^th week of feeding. ②The treatment series was divided into 17-week normal group （n=5）, 17-week model group （n=5） and pioglitazone treatment group （n=7）. Rats in model group were fed with standard diet, while rats in the other two groups were fed with high-fat diet. At the 10^rh week, rats in 17-week pioglitazone treatment group received gastric perfusion of 20 mg/kg per day and rats in the other two groups were administrated with distilled water at the same volume, All rats were executed at the 17^th week of feeding. The final body mass, serum transaminases, blood lipid, blood glucose, insulin as well as hepatic lipid were tested and the pathological changes of liver were observed. RESULTS： A total of 32 rats were involved in the analysis of results.①Results of preventive series： the liver index （liver mass/body mass）, serum triglycerides and liver triglycerides, HO

关 键 词：脂肪肝 噻唑烷二酮类/^＊ 治疗应用 疾病模型 动物 

分 类 号：R575.5[医药卫生—消化系统]